Eligard

Synthetic 9 residue peptide analog of gonadotropin releasing hormone.

Eligard - Pharmacology:

Eligard binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.

Eligard mini report

Eligard NDA
NDA - A product marketed under an approved New Drug Application
Eligard SUBCUTANEOUS
SUBCUTANEOUS
Eligard HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Start - Stop data
START DATA:
2002-May-15
Start - Stop data
STOP DATA
not occurred

Eligard Interactions

Data is temporarily not available

Eligard Contraindications

1. ELIGARDÔ 7.5 mg is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs or any of the components of ELIGARDÔ 7.5 mg. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature.2

2. ELIGARDÔ 7.5 mg is contraindicated in women and in pediatric patients and was not studied in women or children. Moreover, leuprolide acetate can cause fetal harm when administered to a pregnant woman. Major fetal abnormalities were observed in rabbits but not in rats after administration of leuprolide acetate throughout gestation. There were increased fetal mortality and decreased fetal weights in rats and rabbits. The effects on fetal mortality are expected consequences of the alterations in hormonal levels brought about by this drug. The possibility exists that spontaneous abortion may occur.

Generic name, Overdose, Half Life Eligard, Food Interactions, Chemical, etc..

Eligard see also FDA report